


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (currently amended): ~~A composition~~An aqueous composition for pharmaceutical use consisting essentially of:

a thiazole derivative of the formula (I):



wherein


$R^1$  is acyl;

$X$  is a bivalent residue selected from the group consisting of  and 


and may be substituted;

$Y$  is a bond, lower alkylene, lower alkenylene or  $-CONH-$ ; and

$Z$  is a group of the formula:



wherein  $R^2$  is a group of the formula:



(wherein  $G$  is a bond,  $-NHCOCH_2-$  or lower alkylene and  $R^4$  is hydrogen,  $-NH_2$  or lower alkyl);

or a pharmaceutically acceptable salt thereof,


water, and

an additive selected from the group consisting of polyol, sugar alcohol, boric acid and a salt of boric acid,

wherein the thiazole derivative, the water and the additive are present in an aqueous composition for pharmaceutical use.

2. (canceled).

3. (currently amended): The aqueous composition of claim 1, wherein R<sup>2</sup> of the formula (I) is a group of the formula:



(wherein G is a bond, -NHCOCH<sub>2</sub>- or lower alkylene and R<sup>4</sup> is hydrogen or lower alkyl); or a pharmaceutically acceptable salt thereof.

4. (currently amended): The aqueous composition of claim 1, wherein R<sup>1</sup> of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

5. (currently amended): The aqueous composition of claim 1, wherein the thiazole derivative is

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,  
N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,  
N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-[4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl]acetamide,

or

N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide,

or a pharmaceutically acceptable salt thereof.

6. (currently amended): The aqueous composition of claim 1, wherein R<sup>1</sup> of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

7. (currently amended): The aqueous composition of claim 3, wherein R<sup>1</sup> of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.


8. (currently amended): The aqueous composition of Claim 1, wherein the additive is glycerin.

9. (currently amended): The aqueous composition of Claim 1, wherein the additive is mannitol.

10. (currently amended): The aqueous composition of Claim 1, wherein the additive is boric acid or a salt of boric acid.

11. (withdrawn): A method for increasing solubility of a thiazole derivative of the following formula (I) in water, consisting essentially of preparing a composition consisting essentially of:

a thiazole derivative of the formula (I):



wherein


R<sup>1</sup> is acyl;

X is a bivalent residue selected from the group consisting of  and 


and may be substituted;

Y is a bond, lower alkylene, lower alkenylene or -CONH-; and

Z is a group of the formula:



wherein R<sup>2</sup> is a group of the formula:




(wherein G is a bond, -NHCOCH<sub>2</sub>- or lower alkylene and R<sup>4</sup> is hydrogen, -NH<sub>2</sub> or lower alkyl);

or a pharmaceutically acceptable salt thereof,

water, and

an additive selected from the group consisting of polyol, sugar alcohol, boric acid and a salt of boric acid.

12. (withdrawn): The method of claim 11, wherein R<sup>2</sup> of the formula (I) is a group of the formula:



(wherein G is a bond, -NHCOCH<sub>2</sub>- or lower alkylene and R<sup>4</sup> is hydrogen or lower alkyl);

or a pharmaceutically acceptable salt thereof.

13. (withdrawn): The method of claim 11, wherein R<sup>1</sup> of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

14. (withdrawn): The method of claim 11, wherein the thiazole derivative is

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-

(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

or

N-(4-(2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl)-1,3-thiazol-2-yl)acetamide,

or a pharmaceutically acceptable salt thereof.

15. (withdrawn): The method of claim 11, wherein R<sup>1</sup> of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

16. (withdrawn): The method of claim 12, wherein R<sup>1</sup> of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

17. (withdrawn): The method of Claim 11, wherein the additive is glycerin.

18. (withdrawn): The method of Claim 11, wherein the additive is mannitol.

19. (withdrawn): The method of Claim 11, wherein the additive is boric acid or a salt of boric acid.

20. (new): The aqueous composition of Claim 1, wherein the composition is for ocular topical administration.

21. (new): The aqueous composition of Claim 1, wherein the composition further comprises an additive selected from the group consisting of povidone and methylcellulose.